Hong Kong Stock Movement: 3SBIO fell 11.02%, as favorable policies and breakthroughs in AI technology failed to boost market confidence

Hong Kong Stock Movement 3SBIO fell by 11.02%. Based on recent key news: On April 20, Zhitong Finance reported that the MSCI China Healthcare Index rose by 12.3%, but 3SBIO failed to benefit from the favorable policies, and its stock price declined. The government work report listed biomedicine as an emerging pillar industry, and the sector's risk appetite has improved, but 3SBIO's stock price still fell by 11.02%. Source: Zhitong Finance On April 20, Huigang Communications pointed out that breakthroughs in AI pharmaceutical technology and the overseas expansion of Chinese innovative drugs formed a dual resonance, accelerating the industry's fundamentals positively, but 3SBIO's stock price did not reflect this trend. Source: Huigang Communications On April 20, CMB International rated 3SBIO as "Buy" with a target price of HKD 34.87, but the market reaction was poor, and the stock price fell. Source: CMB International, favorable policies for the pharmaceutical sector, risk appetite recovery. Stocks with High Trading Volume in the Industry Kangfang Biotech fell by 11.92%. Based on recent key news: On April 23, Nomura Securities raised the target price for Kangfang Biotech by 27% to HKD 142.75, maintaining a neutral rating. Despite the target price increase, the market was uneasy about the company's undisclosed clinical trial data, leading to a decline in stock price. Source: Huigang Communications On April 21, the American Society of Clinical Oncology announced that clinical project summaries will be reported at the annual meeting from May 29 to June 2. Overall survival data from the HARMONi-6 trial will be presented at the plenary session, but the market's positive expectations for the data did not alleviate stock price pressure. Source: Huigang Communications No other significant news recently. The impact of industry clinical trial data is significant. Innovent Biologics fell by 5.05%. Based on recent key news: On April 21, Innovent Biologics announced a collaboration with a U.S. company to promote the development of innovative drugs. This move may enhance its market competitiveness, but it failed to boost the stock price in the short term, resulting in a 5.05% decline. Source: PR Newswire On April 20, CMB International released a report recommending Innovent Biologics as a buy target with a target price of HKD 113.86. Despite the positive rating, the market reaction was poor, and the stock price still fell. Source: Zhitong Finance On April 20, the MSCI China Healthcare Index rose by 12.3%, but Innovent Biologics did not follow the overall trend, and its stock price fell. Source: Huigang Communications, the valuation repair window for the innovative drug sector is emerging. Rongchang Biologics fell by 6.24%, with a trading volume of HKD 302 million, and there has been no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Stocks with High Market Capitalization in the Industry BeiGene fell by 0.80%. Based on recent key news: On April 21, BeiGene, as the first international innovative pharmaceutical company to achieve profitability, was included in the top ten heavy positions, demonstrating its competitiveness in the innovative drug field. The certainty and growth potential of this combination attracted investor attention, driving stock price fluctuations Data Source: Wind On April 22, the financial report of HengRui Medicine showed its profitability, but the market held a cautious attitude towards its capital allocation strategy, affecting the market sentiment of related innovative pharmaceutical companies. Data Source: Jiemian News On April 21, the valuation of the China Securities Hong Kong Stock Connect Innovative Drug Index fell to a historically low level, showing valuation cost-effectiveness, attracting capital inflow into the innovative drug sector, affecting the stock price of BeiGene. Data Source: Wind The valuation repair window for the innovative drug sector has emerged